MichaelUrbanCallaghanMD
Pediatric Hematology & Oncology • Detroit, MIPediatric Anemia and Red Blood Cell Hematology, Pediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology
Associate Professor, Central Michigan School of Medicine
Dr. Callaghan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3901 Beaubien St
Detroit, MI 48201Phone+1 313-745-4415- Is this information wrong?
Summary
- Dr. Michael Callaghan is a pediatric hematologist/oncologist in Detroit, MI and is affiliated with multiple hospitals in the area, including DMC - Children's Hospital of Michigan and DMC Harper University Hospital. He received his medical degree from Wayne State University School of Medicine and has been in practice 14 years. He is experienced in polycythemia vera, sickle-cell anemia, and pediatric coagulation disorders.
Education & Training
Children's Hospital of MichiganFellowship, Pediatric Hematology/Oncology, 2005 - 2009- Children's Hospital of MichiganResidency, Pediatrics, 2003 - 2005
Wayne State University School of MedicineClass of 2003
Certifications & Licensure
MI State Medical License 2003 - 2026
OH State Medical License 2024 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Dose-Finding Study of SC411 in Children With Sickle Cell Disease Start of enrollment: 2017 Mar 02
Publications & Presentations
PubMed
- 8 citationsConsensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center.Monica L Hulbert, Deepa Manwani, Emily Riehm Meier, Ofelia A Alvarez, R Clark Brown, Michael U Callaghan, Andrew D Campbell, Thomas D Coates, Melissa J Frei-Jones, Jan...> ;Pediatric Blood & Cancer. 2023 Jan 1
- Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies.Karin S Coyne, Brooke M Currie, Michael Callaghan, Kathleen W Wyrwich, Sheryl Pease, Christine L Baker, Steven Arkin, Debra D Pittman> ;European Journal of Haematology. 2022 Sep 1
- 3 citationsUntreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.Michael U Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Víctor Jiménez-Yuste, Mi...> ;Research and Practice in Thrombosis and Haemostasis. 2022 Aug 1
- Join now to see all
Journal Articles
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A Without InhibitorsChristine Kempton, Gallia G Levy, Michael U Callaghan, The New England Journal of Medicine
Abstracts/Posters
- Studying the Role of ETV6 in Megakaryopoiesis and Thrombopoiesis Using a Novel CRISPR-Cas9 Halotag Genome Editing StrategyMichael Callaghan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment CentersMichael Callaghan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response GenesMichael Callaghan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Advances in Hemophilia A: Expert Guidance and Practical Case Discussions61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
UniQure Offers a Closer Look at the Leading Hemophilia B Gene TherapyDecember 8th, 2020
Hospital Affiliations
DMC Children's Hospital of MichiganDetroit, Michigan
DMC Harper University HospitalDetroit, Michigan
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
